BiotechTube

Rosuvastatin 40mg + Placebo

Pre-clinicalRecruiting
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Coronary Artery Disease

Conditions

Coronary Artery Disease, Atherosclerotic Plaque, Coronary Computed Tomography Angiography, Statin Therapy, Multidetector Computed Tomography, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Vascular Diseases, Hyperlipidemia

Trial Timeline

May 28, 2025 → Dec 15, 2028

NCT ID
NCT06603363

About Rosuvastatin 40mg + Placebo

Rosuvastatin 40mg + Placebo is a pre-clinical stage product being developed by HeartFlow for Coronary Artery Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06603363. Target conditions include Coronary Artery Disease, Atherosclerotic Plaque, Coronary Computed Tomography Angiography.

What happened to similar drugs?

20 of 20 similar drugs in Coronary Artery Disease were approved

Approved (20) Terminated (2) Active (0)
✅EvolocumabHeartFlowApproved
✅Clopidogrel treatment groupYuhanApproved
✅high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
✅statins, ezetimibe + Combination therapyYuhanApproved
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
✅PrasugrelDaiichi SankyoApproved
✅Prasugrel + ClopidogrelDaiichi SankyoApproved

Hype Score Breakdown

Clinical
3
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06603363Pre-clinicalRecruiting

Competing Products

20 competing products in Coronary Artery Disease

See all competitors
ProductCompanyStageHype Score
EvolocumabHeartFlowApproved
29
High intensity lipid loweringHeartFlowPre-clinical
20
ExenatideEli LillyPhase 3
40
Clopidogrel treatment groupYuhanApproved
50
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
high-dose rosuvastatin + low-dose rosuvastatin plus ezetimibeYuhanApproved
43
Sarpogrelate + Aspirin + Clopidogrel + Placebo (for Sarpogrelate)YuhanPhase 3
40
statins, ezetimibe + Combination therapyYuhanApproved
50
YH14659 + clopidogrel & aspirinYuhanPhase 1
29
Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
43
clopidogrel + prasugrelDaiichi SankyoPhase 1
21
PrasugrelDaiichi SankyoApproved
43
ADP receptor inhibitorsDaiichi SankyoPre-clinical
26
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel + ClopidogrelDaiichi SankyoPhase 2
35
prasugrel + clopidogrelDaiichi SankyoPhase 1
29
Prasugrel + ClopidogrelDaiichi SankyoApproved
43
Triple oral lipid lowering treatmentDaiichi SankyoPhase 3
47
Placebo + PrasugrelDaiichi SankyoPhase 3
40
30-day DAPT + Guideline-directed therapyDaiichi SankyoApproved
50